       Document 0428
 DOCN  M9610428
 TI    [Uveitis with hypopyon in patients with acquired immunodeficiency
       syndrome, treated with Rifabutin]
 DT    9601
 AU    Frau E; Gregoire-Cassoux N; Hannouche D; Lautier-Frau M; Vittecoq D;
       Offret H; Service d'Ophtalmologie, CHU de Bicetre.
 SO    J Fr Ophtalmol. 1995;18(6-7):435-8. Unique Identifier : AIDSLINE
       MED/96008824
 AB    BACKGROUND: Iridocyclitis has been identified as a dosage-dependent side
       effect in patients with the acquired immunodeficiency syndrome who are
       treated for Mycobacterium avium complex infections with systemic
       Rifabutin. We reviewed cases of acute hypopyon uveitis occurring in
       patients with AIDS to establish whether there was an association or not.
       METHODS: All patients were referred by an infection disease specialty
       service for complete ophthamological evaluation and ancillary
       laboratory. Six patients with AIDS, aged from 29 to 65 years, presented
       with acute unilateral hypopion. RESULTS: At the time of presentation,
       all six patients were receiving treatment for MAC infection with
       Rifabutin (dosage range, 300-600 mg/d) and four received Fluconazol.
       Results of microbiological investigations were negative. Hypopyon
       developed in the second eye of two patients. Hypopion resolved rapidly
       with intensive antibiotherapy without corticosteroids. CONCLUSION:
       Concomitant use of Rifabutin and Fluconazol may precipitate hypopyon
       uveitis. The cause of the uveitis is less certain, but the possible role
       of a microbiological agent cannot be ruled out.
 DE    Adrenal Cortex Hormones/THERAPEUTIC USE  Adult  Antibiotics,
       Antitubercular/THERAPEUTIC USE  Antibiotics, Combined/THERAPEUTIC USE
       AIDS-Related Opportunistic Infections/*DRUG THERAPY  Drug Interactions
       English Abstract  Female  Human  Male  Middle Age  Mycobacterium
       avium-intracellulare Infection/*DRUG THERAPY  Retrospective Studies
       Rifabutin/*ADVERSE EFFECTS/THERAPEUTIC USE  Suppuration/CHEMICALLY
       INDUCED/ETIOLOGY  Uveitis/*CHEMICALLY INDUCED/ETIOLOGY  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

